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Genomic variation is a trend observed in various human diseases including cancer. Genetic
studies have set out to understand howandwhy these variations result in cancer, why some
populations are pre-disposed to the disease, and also how genetics affect drug responses.
The melanoma incidence has been increasing at an alarming rate worldwide. The burden
posed by melanoma has made it a necessity to understand the fundamental signaling
pathways involved in this deadly disease. Signaling cascades such as mitogen-activated
protein kinase and PI3K/AKT have been shown to be crucial in the regulation of processes
that are commonly dysregulated during cancer development such as aberrant proliferation,
loss of cell cycle control, impaired apoptosis, and altered drug metabolism. Understanding
how these and other oncogenic pathways are regulated has been integral in our challenge
to develop potent anti-melanoma drugs.With advances in technology and especially in next
generation sequencing, we have been able to explore melanoma genomes and exomes
leading to the identiﬁcation of previously unknown genes with functions in melanomagen-
esis such as GRIN2A and PREX2. The therapeutic potential of these novel candidate genes
is actively being pursued with some presenting as druggable targets while others serve as
indicators of therapeutic responses. In addition, the analysis of the mutational signatures
of melanoma tumors continues to cement the causative role of UV exposure in melanoma
pathogenesis. It has become distinctly clear that melanomas from sun-exposed skin areas
have distinct mutational signatures including C to T transitions indicative of UV-induced
damage. It is thus necessary to continue spreading awareness on how to decrease the
risk factors of developing the disease while at the same time working for a cure. Given
the large amount of information gained from these sequencing studies, it is likely that in
the future, treatment of melanoma will follow a highly personalized route that takes into
account the differential mutational signatures of each individual’s cancer.
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INTRODUCTION
The incidence of melanoma has been rising at an alarming rate
in both men and women especially in the Caucasian population
(Purdue et al., 2008). According to the American Cancer Society,
the lifetime risk of developing melanoma currently stands at 2%
in whites, 0.1% in blacks, and 0.5% in Hispanics (American Can-
cer Society, 2012). It has been proposed that this increase is a
result of correction in underreporting through the Surveillance,
Epidemiology, and End Results (SEER) program (Cockburn et al.,
2008), increased surveillance and diagnosis (Jemal et al., 2001),
and an increase in risky behaviors such as indoor tanning (Arm-
strong and Kricker, 2001; Lazovich et al., 2010). Regardless of the
cause of rise in incidence, an increase in survival after a diagnosis
of metastatic melanoma has also been noted with the develop-
ment of new therapies. Targeted therapies such as vemurafenib
(Chapman et al., 2011) have emerged from advances in genetic
proﬁling of molecular targets and it is expected that as new targets
are identiﬁed, novel therapies will continue to emerge. Three key
molecular pathways have been found to be highly deregulated in
melanoma: mitogen-activated protein kinase (MAPK), as a result
of mutations in RAS, RAF, and KIT ; PI3K/AKT, as a consequence
of mutations in RAS, mutations or loss of PTEN (phosphatase
and tensin homolog) and dysregulated expression of AKT, and
p16INK4A due to mutations in CDKN2A, ARF, and p53. Vari-
ous strategies of targeting melanoma have emerged based on the
information gained from analyses of these pathways with vary-
ing success. Molecular genome screens of tumor samples have
been instrumental in identifying novel targets in melanoma. In
this review, we will discuss the aforementioned pathways as well
as novel emerging targets identiﬁed in large-scale tumor genome
proﬁling studies.
MITOGEN-ACTIVATED PROTEIN KINASE (RAS/RAF/MEK/ERK)
PATHWAY
The MAPK pathway is a highly conserved signaling cascade
involved in various cellular functions including cell proliferation,
differentiation, and migration. This pathway can be activated by
the stimulation of upstream signalingmolecules including growth
factor receptors andG protein-coupled receptors (Wellbrock et al.,
2004a; Gray-Schopfer et al., 2007). The aberrant activation of the
classical MAPK pathway with extracellular signal-regulated kinase
(ERK) as the terminal kinase is a frequent event in human cancer
and is often the result of activating mutations in the oncogenes;
BRAF (7%; Davies et al., 2002) and RAS (15–30%; Bos, 1989)
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based on analyses of all cancer types. It is interesting to note that
mutations of RAS and RAF are mutually exclusive in associated
malignancies including melanoma (Brose et al., 2002).
RAS
The RAS proteins (H, K, and N-RAS) are small GTPases local-
ized on the inner leaﬂet of the plasma membrane where they
serve as critical mediators of cell growth, proliferation and dif-
ferentiation (Trahey andMcCormick, 1987; Lowy andWillumsen,
1993). RAS activity is controlled through cycling between a guano-
sine diphosphate (GDP)-bound state (inactive) and a guanosine
triphosphate (GTP)-bound state (active; Downward, 1996; Schef-
fzek et al., 1997). The cycling between GDP- and GTP-bound
state is partially controlled by the intrinsic GTPase activity of
RAS, the activity of GTPase-activating proteins (GAPs) which
promote the formation of inactive RAS–GDP complexes, and
guanine-nucleotide exchange factors (GEFs) that accelerate the
formation of RAS–GTP complexes (Cales et al., 1988; Herrmann
et al., 1996). Mutations in the RAS genes abolish the intrinsic
GTPase activities of these molecules and also reduce sensitiv-
ity to GAPs by preventing the dissociation of GTP (Trahey and
McCormick, 1987; Scheffzek et al., 1997;Wittinghofer et al., 1997).
GTP-bound RAS is able to activate its effector molecules such as
RAF (Marais et al., 1995) and phosphatidylinositol-3-OH kinase
(PI3K; Rodriguez-Viciana et al., 1994), and it is through the acti-
vation of these effectors that RAS is able to regulate proliferation,
survival, and processes linked to tumorigenic cell transformation.
The MAPK pathway can also be stimulated by phosphorylation
of RAF by RAS (Marais et al., 1995; Weber et al., 2001), which
in turn phosphorylates and activates MAPK kinases 1 and 2
(MEK1 andMEK2), which then phosphorylate and activate ERK1
and ERK2 (Rubinfeld and Seger, 2004; Rapp et al., 2006). Acti-
vated ERK1/2 phosphorylates numerous transcription factors that
control gene expression such as ELK1 (Babu et al., 2000), FOS
(Monje et al., 2005), and c-JUN (Lopez-Bergami et al., 2007).
RAS can also activate the PI3K/AKT signaling cascade through its
interactions with the p110 catalytic subunit of PI3K (Rodriguez-
Viciana et al., 1994; Pacold et al., 2000) leading to activation,
translocation to the membrane, and conformational changes
of the lipid kinase. PI3K phosphorylates phosphatidylinositol
4,5-bisphosphate [PtdIns(4,5)P2] to produce phosphatidylinos-
itol 3,4,5-trisphosphate [PtdIns(3,4,5)P3], a second messenger
that binds to a large number of proteins such as AKT/protein
kinase B (PKB; Haslam et al., 1993; Datta et al., 1995; Franke et al.,
1995) through pleckstrin homology domains. AKT is a modula-
tor of oncogenic transformation (Mirza et al., 2000), cell survival
(Edinger and Thompson, 2002), apoptosis (Cheung et al., 2008),
cell cycle progression (Liang et al., 2002), and glycogen synthesis
(Cross et al., 1995).
N-RAS is the most commonly mutated RAS isoform in human
melanoma and melanocytic nevi (Der et al., 1986; Trahey and
McCormick, 1987; Trahey et al., 1987). Mutational analyses have
shown that ∼56% of congenital nevi exhibit RAS mutations in
comparison to 33% of primary and 26% of metastatic melanomas
(Albino et al., 1989; Jafari et al., 1995; Demunter et al., 2001). Acti-
vating RAS mutations are associated with sun and UV exposure
and are more common in tumors under continuous UV exposure
(56%) than tumors from intermittently or non-sun-exposed sites
(21%; Ball et al., 1994; Jafari et al., 1995; van Elsas et al., 1996). The
most frequent observed mutations are in codons 12, 13, and 61
and they lead to the loss of the intrinsic GTPase activity of RAS
resulting in constitutive signaling and activation of downstream
cascades (Der et al., 1986; Trahey and McCormick, 1987; Trahey
et al., 1987). This improper signaling has been shown to promote
aberrant cell proliferation (Dumaz et al., 2006), metastasis (Ack-
ermann et al., 2005), inhibition of apoptosis (Kodaki et al., 1994;
Eskandarpour et al., 2005), and chemoresistance (Kodaki et al.,
1994; Rodriguez-Viciana et al., 1994).
Activating mutations of K-RAS in melanoma appear to be an
extremely rare event occurring in only 2% of cases, with the
most common missense mutation found in codon 12 (Shukla
et al., 1989; Milagre et al., 2010). This mutation has been shown
to induce anchorage-independent growth in melanocytes trans-
formedwithK-RASG12V ; however, it is less tumorigenic compared
to cells transformed with N-RASG12V indicating that K-RAS may
be aweaker oncogene thanN-RAS inmelanocytes (Whitwamet al.,
2007). H-RAS mutations are also rare, detected only in 1% of
melanomas (Milagre et al., 2010), especially sporadic melanomas
and Spitz nevi likely from ampliﬁcation of its genomic locus on
chromosome 11p and oncogenic point mutations (Bastian et al.,
2000). In animal models, tumorigenicity of mutant H-RasG12V
has been shown to be enhanced inmice with deletions in p16Ink4a
(Chin et al., 1997, 1999), mutation of p53 (Bardeesy et al., 2001),
or UV exposure (Hacker et al., 2005).
Given the role that RAS plays in cancer, various therapeutic
strategies for targeting this oncogenic protein have emerged. Most
challenging however, is the search for small molecule inhibitors
that can directly target RAS through binding to active sites or bind-
ing pockets (Gysin et al., 2011). Several small molecule inhibitors
that can suppress RAS activation by preventing guanine exchange
through inhibition of RAS–GEF interactions have been identiﬁed
(Taveras et al., 1997; Colombo et al., 2004; Peri et al., 2005). These
small molecules bind to a cleft on the switch 2 region (residues
60–76) but their therapeutic potential is unknown. Inhibitors
that target post-translational modiﬁcations of RAS have also been
explored for therapeutic purposes. The attachment of a farne-
syl isoprenoid group to RAS proteins is required for localization
to the plasma membrane and activity (Kohl et al., 1995). Several
farnesyltransferase inhibitors have been identiﬁed through ratio-
nal design strategies (Dinsmore and Bell, 2003) and compound
library screens (Sebti and Hamilton, 2000). These inhibitors have
been shown to suppress the activity of mutated, constitutively
active RAS in vitro (Kohl et al., 1995; Sebti and Hamilton, 2000)
and tumor growth in vivo (End et al., 2001; Gunning et al., 2003).
Despite these promising results, clinical validation of several of
these inhibitors did not show objective responses in most solid
tumors (Sharma et al., 2002). In melanoma, a phase II clinical
trial of the farnesyltransferase inhibitor, R115777 (tipifarnib) as
a single agent did not show any beneﬁt (Gajewski et al., 2006).
Furthermore, in a recently completed trial, tipifarnib in combi-
nation with sorafenib or temsirolimus did not show any activity
to justify continued use (Margolin et al., 2012). Failures of far-
nesyltransferase inhibitors in vivo and in clinical trials have been
attributed to RAS prenylation and reactivation via geranylgeranyl
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transferase type 1 (Britten et al., 2001; Lobell et al., 2001). The
speciﬁcity of R115777 is to the rarely mutated H-RAS, instead of
the more frequently mutated N-RAS or K-RAS, and has also been
speculated to be a major cause of the reduction in efﬁcacy (James
et al., 1996; Baines et al., 2011). Success in targeting melanomas
with RAS mutations may be achieved by inhibiting RAS effec-
tor pathways through combined targeting of BRAF, MEK, and
PI3K/AKT/mammalian target of rapamycin (mTOR) due to the
integral role of these effectors in RAS driven transformation as
well as the availability of clinically tested small molecule inhibitors
(Davies et al., 2007; Engelman et al., 2008; Fasolo and Sessa, 2008;
Lee et al., 2010; Gysin et al., 2011).
BRAF
BRAF is a serine/threonine kinase, a component of the MAPK
pathway downstream of RAS and when activated, triggers phos-
phorylation of MEK (Johnson and Lapadat, 2002). Mutations in
BRAF are prevalent in human cancers (7%) with the highest inci-
dences found inmalignantmelanoma (27–70%), papillary thyroid
cancer (36–53%), colorectal cancer (5–22%), and serous ovarian
cancer (30%; Davies et al., 2002; Kumar et al., 2003; Pollock et al.,
2003a; Young et al., 2005). Of the over 40 BRAF activating muta-
tions identiﬁed, the BRAFV600E mutation is the most common,
and accounts for 92% of BRAF mutations in sporadic melanomas
and 82% of benign nevi, implying that it might be involved in
the progression from a benign to a cancerous state (Davies et al.,
2002; Kumar et al., 2003; Pollock et al., 2003a). A single-base mis-
sense transversion (T to A at nucleotide 1,799) changes valine to
glutamic acid in codon 600 (V600E) of exon 15, and results in
constitutive activation of the RAF kinase (Davies et al., 2002; Gar-
nett andMarais, 2004;Wan et al., 2004). Given the presence of the
BRAFV600E mutation in benign melanocytic nevi (Pollock et al.,
2003a), pre-malignant colon polyps and early stage colorectal can-
cer (Yuen et al., 2002; Ikehara et al., 2005), the oncogenic potential
of mutated BRAF has been under investigation. BRAFV600E was
shown to transform NIH3T3 ﬁbroblasts and mouse melanocytes
resulting in increased proliferation in vitro, stimulation of ERK
and tumorigenesis in vivo (Houben et al., 2004; Ikenoue et al.,
2004; Wan et al., 2004; Wellbrock et al., 2004a). Interestingly,
benign melanocytic nevi with BRAF mutations exhibit growth
arrest characteristics including the expression of the senescence
marker, β-galactosidase (Michaloglou et al., 2005; Gray-Schopfer
et al., 2006; Dhomen et al., 2009). This might suggest that other
mutations are required to drive oncogenesis in nevi, which is sup-
ported by studies such as those showing that loss of p53 results in
the progression to melanoma (Patton et al., 2005). However, it is
still possible that the benign nevi with mutated BRAF can escape
the oncogene-induced senescence and become melanomas, which
might explain the high percentage of this mutation in sporadic
melanoma (Wellbrock et al., 2004b; Dhomen et al., 2009). The
effects of other less frequent observed BRAF mutations have also
been investigated. Among melanomas with mutated BRAF, the
BRAFV600K mutation is observed in 12%of cases while BRAFV600R
and BRAFV600D are each observed at a frequency of ∼5% (Lovly
et al., 2012). These mutations, similar to BRAFV600E result in an
increase in BRAF kinase activity and increased MEK and ERK
phosphorylation (Wan et al., 2004).
The high prevalence of the BRAFV600E mutation in melanoma
has made it a popular target in drug development. Small kinase
inhibitors have yielded mixed results with some showing greater
efﬁcacy than others. Sorafenib (Nexavar, Bay 43-9006), was ini-
tially produced as a speciﬁc inhibitor of CRAF and was found
to also have inhibitory activity toward BRAF (Lyons et al., 2001;
Wilhelm et al., 2004). Further investigation showed that sorafenib
not only inhibited wild-type BRAF, but mutant BRAF as well.
Additionally, it also asserts inhibitory activity toward various
receptor tyrosine kinases critical in cancerous processes includ-
ing vascular endothelial growth factor receptor (VEGFR) 1/2/3,
platelet-derived growth factor receptor β (PDGFR-β), ﬁbroblast
growth factor receptor 1 (FGFR-1), c-KIT, FLT-3, and RET (Wil-
helm et al., 2004; Carlomagno et al., 2006; Lierman et al., 2006;
Chang et al., 2007). Various studies have shown the potential of
sorafenib in inhibiting the growthof a host ofmalignancies includ-
ing melanoma, leukemia, hepatocellular carcinoma, esophageal
carcinoma in vitro and in vivo (Wilhelm et al., 2004; Sharma
et al., 2005), and is successfully utilized in the treatment of renal
cell carcinoma (Escudier et al., 2009). Single agent sorafenib for
melanoma treatment has been largely unsuccessful, with efﬁcacy
improved when used in conjunction with chemotherapy or adju-
vant immunotherapy (Eisen et al., 2006; McDermott et al., 2008;
Amaravadi et al., 2009; Augustine et al., 2010; Ott et al., 2010;
Egberts et al., 2011).
Small molecule inhibitors with greater speciﬁcity to mutant
BRAFV600E than the wild-type protein have been developed.
SB590885 (GlaxoSmithKline, Collegeville, PA, USA) was shown
to have 100-fold more activity than sorafenib in inhibiting BRAF
activity (King et al., 2006). Sorafenib stabilizes the inactive con-
formation of the kinase while SB590885 stabilizes the active BRAF
conformation, which explains the difference in activity and might
make SB590885 a better candidate for clinical development (King
et al., 2006). Vemurafenib (PLX4720/RG7204), a novel BRAF
inhibitor with high speciﬁcity to BRAFV600E has potent cytotox-
icity against melanoma cells in vitro and in vivo and clinically
has improved survival of melanoma patients (Tsai et al., 2008;
Yang et al., 2010; Chapman et al., 2011; Young et al., 2012). It also
appears that similar to the BRAFV600E mutations, the BRAFV600D,
BRAFV600K, and BRAFV600R mutations are also responsive to inhi-
bition by vemurafenib in pre-clinical trials (Rubinstein et al., 2010;
Yang et al., 2010). In clinical trials, BRAFV600K and BRAFV600E
both show better responses to theMEK inhibitor, trametinib com-
pared to dacarbazine therapy and also when compared to patients
with wild-type BRAF tumors (Flaherty et al., 2012).
During a phase I clinical trial of vemurafenib, 81% of patients
with BRAFV600E mutations demonstrated signiﬁcant shrinkage of
liver, bowel, and bone metastases and progression-free survival
of 7 months (Flaherty et al., 2010). The follow-up phase II trial
showed a response rate of 52% (Bollag et al., 2010). Meanwhile,
48% of patients showed a partial response in a phase III trial, with
0.9% complete responses observed (Chapman et al., 2011). The
limiting factor in patient treatment with vemurafenib appears to
be innate and acquired resistance. Furthermore, it appears that
there are alterations in signaling after BRAF inhibitor exposure
that may promote cell growth indicating that meticulous selection
of treatment candidates is necessary. This is especially important
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because some patients treated with vemurafenib present with
dermatological side effects that include keratoacanthomas and
squamous cell carcinomas (Oberholzer et al., 2012; Su et al., 2012).
Reports indicate that BRAF inhibitors induce ERK signaling and
increase growth in wild-type BRAF cells (Heidorn et al., 2010;
Poulikakos et al., 2010). Further studies have shown that expo-
sure to BRAF inhibitors results in increased binding of BRAF to
CRAF, especially in RAS mutant cells leading to hyperactivation
of CRAF, and elevated ERK signaling (Hatzivassiliou et al., 2010).
Subsequent analysis showed that this increase was as a result of
transactivation of RAF dimers by BRAF inhibitors (Hatzivassil-
iou et al., 2010; Poulikakos et al., 2010). The binding of a BRAF
inhibitor to one protomer within a RAF dimer was found to
result in loss of the catalytic activity of the inhibitor-bound RAF
and transactivation of the other protomer. This transactivation
of RAF homo- and heterodimers is likely responsible for induc-
tion of MEK/ERK phosphorylation by RAF inhibitors in cells with
wild-type BRAF. The keratoacanthomas and squamous cell car-
cinomas observed in vemurafenib treated patients show a high
rate of RASmutations and increased ERK signaling despite having
the BRAFV600E mutation and treatment with the drug suggest-
ing that the RAS mutations may pre-dispose the patients to these
dermal lesions. Acquired resistance mechanisms are also under
investigation. Recently, it has been shown that innate resistance
to vemurafenib can be attributed to the secretion of hepatocyte
growth factor (HGF) by the tumor micro-environment (Strauss-
man et al., 2012). This results in the activation of theHGF receptor,
MET, which can reactivate the MAPK and PI3K/AKT pathways
(Straussman et al., 2012). Other mechanisms of acquired resis-
tance have also been attributed to reactivation of the MAPK
and PI3/AKT pathways via development of N-RAS mutations
(Nazarian et al., 2010), activation of AKT (Shao and Aplin, 2010),
up-regulation and enhanced activation of the receptor tyrosine
kinases PDGFR-β (Nazarian et al., 2010), COT/MAP3K8 (Johan-
nessen et al., 2010), insulin-like growth factor 1 receptor (IGF-1R),
FGFR3 (Yadav et al., 2012), emergence of an aberrantly spliced
BRAF variant [p61BRAF(V600E); Poulikakos et al., 2011] and
increases in BRAFV600E copy number (Shi et al., 2012). Other
BRAF inhibitors such as GDC0879 (Hoeﬂich et al., 2009; Wong
et al., 2009) and GSK2118436/dabrafenib (Anforth et al., 2012;
Hauschild et al., 2012) are currently in the development and test-
ing phase to determine their efﬁcacy in melanoma treatment. In
clinical testing, dabrafenib was shown to improve progression-
free survival with durable responses at 6 months (Falchook et al.,
2012b; Hauschild et al., 2012).
To circumvent the innate and acquired resistance prob-
lem, combinations of BRAF inhibitors with inhibitors of other
kinases and pathways that promote melanoma growth are being
investigated. Co-inhibition of BRAFV600E with MEK (Flaherty
et al., 2012; Shi et al., 2012), PI3K/mTOR (Greger et al., 2012),
metabotropic glutamate receptor 1 (Lee et al., 2011;Mehnert et al.,
2012), histone deacetylases (Lai et al., 2012), Hsp90 (Catalanotti
and Solit, 2012), and cytotoxic T lymphocyte antigen 4 (CTLA-4;
Weber et al., 2012) are actively being pursued. The combination of
vemurafenib and the CTLA-4 blocker, ipilimumab, is thought to
be especially promising as evidence suggests that BRAF inhibitors
and immunotherapymay act synergistically (Ascierto et al., 2012).
Pre-clinical studies indicate that exposure to high concentrations
of PLX4720 does not affect the viability and function of lym-
phocytes (Comin-Anduix et al., 2010). Furthermore, other studies
have shown that PLX4720 treated cells become better targets
for immunotherapy due to increased expression of melanocyte
differentiation antigens which confer enhanced antigen-speciﬁc
recognition by CTLs (Boni et al., 2010).
MEK1/2
MEK1/2 are kinases that phosphorylate tyrosine and threonine
residues on ERK1/2 kinases (Roskoski, 2012). MEKmutations are
rare in human cancers with minimal mutated cases detected in
lung cancer (Marks et al., 2008; Sasaki et al., 2010) and ovarian
cancer (Estep et al., 2007). Analyses of human melanoma tumors
have also shown a low incidence (3–8%) of somatic mutations
in MEK (Murugan et al., 2009; Nikolaev et al., 2012). Regardless,
MEK inhibitors have emerged as an effective strategy to target drug
resistant BRAFV600E melanomas in patients with or without pre-
vious exposure to BRAF inhibitors (Gilmartin et al., 2011; Wagle
et al., 2011). Trametinib (Falchook et al., 2012a; Flaherty et al.,
2012) and selumetinib (Boers-Sonderen et al., 2012) have emerged
as potent MEK inhibitors. Pre-clinical studies show that cells with
mutated BRAF are sensitized to AZD-6244/selumetinib (Prickett
et al., 2011; Dahlman et al., 2012), TAK-733 (Dahlman et al., 2012).
Furthermore, clinical studies have also shown thatMEK inhibitors
increase sensitization to BRAF inhibition with improved survival
achieved in patients treated with combination MEK and BRAF
inhibitors compared to either drug alone (Flaherty et al., 2012).
PI3K/AKT PATHWAY
Activation of the PI3/AKT pathway is one of the most frequent
events in cancer. This pathway is a critical player not only in nor-
mal physiological processes but also in tumorigenic development
through the positive regulation of G1/S phase progression, inhi-
bition of apoptotic cell death, and increased survival (Cully et al.,
2006; Jiang and Liu, 2008; Yuan and Cantley, 2008). When acti-
vated by any one of a variety of mechanisms including activated
receptor tyrosine kinases (Domchek et al., 1992), interactions
with growth factor receptor-bound protein 2 (GRB2) adaptor
protein (Pawson, 2004), or RAS (Kodaki et al., 1994; Rodriguez-
Viciana et al., 1994; Chan et al., 2002), the second messenger lipid
PtdIns(3,4,5)P3 is generated. PtdIns(3,4,5)P3 in turn recruits both
phosphatidylinositol-dependent kinase 1 (PDK1) and AKT/PKB
to the membrane where PDK1 phosphorylates and activates
AKT/PKB and indirectly activates the mTOR (Hay and Sonen-
berg, 2004; Sarbassov et al., 2005). Activated AKT has multiple
functions including increased oncogenic transformation, survival,
proliferation, insulin metabolism, and cell cycle regulation (Stam-
bolic et al., 1998; Mirza et al., 2000; Shin et al., 2002, 2010; Stahl
et al., 2004). AKT can also directly phosphorylate mTOR through
phosphorylation (and inactivation) of tuberous sclerosis complex
2 (TSC2), an inhibitor of mTOR (Ma et al., 2005). The activation
of mTOR has been shown to be involved in regulation of glucose
availability in the cell and tumorigenesis (Kim et al., 2003; Sar-
bassov et al., 2005). Dysregulation of the PI3K/AKT pathway in
cancer can occur as result of mutations in the gene encoding the
p110 catalytic subunit of PI3K, PI3KCA subunit (Samuels et al.,
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2004), loss of the tumor suppressor PTEN, a negative regulator
of PI3K/AKT pathway (Li et al., 1997) or molecular alterations in
AKT (Staal, 1987; Bellacosa et al., 1995; Cheung et al., 2008). In
melanoma, PTEN loss and AKT ampliﬁcation are common events
and have been well documented.
PHOSPHATASE AND TENSIN HOMOLOG
The tumor suppressor on chromosome 10, PTEN (deleted on
chromosome 10) acts as a negative regulator of the phosphatidyli-
nositol 3-kinase (PI3K) signaling pathway and has been implicated
in a multitude of cancers. PtdIns(3,4,5)P3 is a key cell signaling
molecule catalyzed from PtdIns(4,5)P2 by PI3K (Salmena et al.,
2008). PTEN hydrolyzes the 3-phosphate on PtdIns(3,4,5)P3 to
generate PIP2, and thereby negatively regulates PtdIns(3,4,5)P3-
mediated downstream signaling (Stambolic et al., 1998; Carracedo
and Pandolﬁ, 2008). Upon PTEN loss, PtdIns(3,4,5)P3 accumu-
lates and promotes the recruitment of a subset of proteins that
contain a pleckstrin homology domain to cellular membranes,
including the serine/threonine kinases AKT1, AKT2, AKT3, and
PDK1 (Stambolic et al., 1998). Deletion,mutation, or inactivation
of PTEN results in aberrant activation of PI3K pathway effectors
(Stambolic et al., 1998; Suzuki et al., 1998). Various alterations in
PTEN have been identiﬁed in melanoma including allelic loss in
20%of melanomas, altered expression in 40%of tumors and hem-
izygous deletions and inactivation in 57–60% of melanoma cell
lines (Pollock et al., 2002; Goel et al., 2006; Li and Ross, 2007; Yin
and Shen, 2008). Ectopic expression of PTEN in melanoma cells
lacking functional protein has been shown to inhibit AKT phos-
phorylation, increase apoptosis, and decrease cell proliferation
(Stewart et al., 2002). siRNA knockdown of wild-type PTEN has
been shown to result in increased phosphorylation of AKT3 and
radial growth reinforcing its involvement in melanoma pathogen-
esis (Stahl et al., 2004). The lack of functional PTEN also appears
to regulate cell survival by increasing BCL-2 expression and pro-
moting insensitivity to chemotherapeutic agents (Wu et al., 2003;
Stahl et al., 2004; Madhunapantula et al., 2007). In melanoma, the
loss of PTEN is thought to occur early in melanomagenesis as
shown in primary lesions harboring loss of one allele of PTEN,
or PTEN haplo-insufﬁciency due to the loss of the entire chro-
mosome 10 (Parmiter and Nowell, 1988; Bastian et al., 1998; Wu
et al., 2003). Several studies have shown that PTEN loss can inter-
act with other melanoma mutations. Bosenberg’s group elegantly
demonstrated that in a genetically modiﬁed mutated BRAF trans-
genic mouse model, the deletion of a functional PTEN can drive
the development of malignant melanoma (Dankort et al., 2009).
Furthermore, other studies have identiﬁed functional redundancy
between PTEN loss and RAS mutation and have shown that these
two genes are mutually exclusive in melanoma development due
to redundant activation of the PI3K/AKT pathways (Tsao et al.,
2000, 2004). De novo Ras mutations have been observed in a
mousemodel of Pten+/+ mice while Pten+/− melanomas showed
a decreased incidence of Ras mutations, while Pten−/− mice com-
pletely lacked Rasmutations (Mao et al., 2004). Furthermore, Tsao
et al. (2000) observed similar results in humanmelanoma cell lines
where cells with PTEN loss lacked RAS mutations. Similarly, a
mouse model of Tyr-H-RASV21Gink4a/Arf−/− in a Pten+/+ or
Pten+/− background showed that inactivation of one copy of
Pten led to earlier onset of melanoma whereas mice without acti-
vated Ras in the Pten+/−Ink4aArf−/− background did not give
rise to animals with melanoma (Nogueira et al., 2010). Taken
together, these studies suggest that activation of Ras and loss of
Pten cooperates in a subset of melanomas. However, exceptions
in the reciprocity of NRAS mutations and PTEN loss have been
noted. In the study by Tsao et al. (2000), they found that one cell
line in their cohort had concurrent loss of PTEN with an NRAS
mutation. Similarly, Nogueira et al. (2010) found that ∼14% of
the human melanomas they analyzed had an NRAS mutation in
addition to loss of PTEN. It is possible that a small population
that harbors both RAS and PTEN mutations has escaped from
signaling through the PI3K pathway and instead its tumorigenic
properties are driven by the MAPK pathway.
AKT
Phosphatidylinositol (3,4,5)-triphosphate directly binds to PDK1
which can phosphorylate and activate AKT (Alessi et al., 1997;
Currie et al., 1997). AKT has three isoforms; AKT1, AKT2, and
AKT3 with each encoded for by different genes which share a
high degree of structural similarities (Staal, 1987; Nakatani et al.,
1999). Upon PtdIns(3,4,5)P3 binding, PDK1 induces AKT kinase
activity 30-fold by phosphorylating it on the catalytic domain
on residue threonine 308, or through phosphorylation on the
carboxy-terminal hydrophobic motif on serine 473 by PDK2
(Alessi et al., 1997; Toker and Newton, 2000). Phosphorylation
of both sites has been shown to be essential for maximal activation
of AKT (Alessi et al., 1996). These activated AKT serine/threonine
kinases, in turn are thought to phosphorylate∼9,000 proteinswith
the minimal recognition sequence: R-X-R-X-X-S/T in both the
cytoplasm and the nucleus (Lawlor and Alessi, 2001). These pro-
teins are involved in regulating the cell cycle, preventing apoptosis,
and triggering cellular growth (Manning and Cantley, 2007).
Expression of these three AKT isoforms has been shown to
be differential among tissues. AKT1 is ubiquitously expressed in
most organs and tissues at high levels; AKT2 expression is prefer-
entially elevated in insulin-sensitive tissue such as the liver,muscle,
and adipose tissue while AKT3 is predominantly expressed in the
brain and testis (Dong et al., 1999; Zinda et al., 2001; Franke,
2008); expression however does not always imply activation (Stahl
et al., 2004). All three isoforms of AKT have been linked to can-
cers of the stomach, breast, pancreas, and ovary (Staal, 1987;
Cheng et al., 1992, 1996; Bellacosa et al., 1995). Dysplastic nevi
and melanomas display increased AKT phosphorylation in con-
trast to normal or slightly dysplastic nevi (Dhawan et al., 2002).
AKT2 and AKT3 have emerged as the predominant forms that
are dysregulated in melanoma. Activated AKT3 has been detected
in 43–60% of sporadic metastatic melanoma when compared to
normal melanocytes, an observation attributed to increased copy
number of the AKT3 gene (Stahl et al., 2004). Additionally, levels
of phosphorylated AKT3 were found to correlate with melanoma
progression suggesting that AKT3 might have a role in the aggres-
siveness of melanomas (Stahl et al., 2004). In addition to the
increase in copy number that leads to improper AKT3 activation,
loss of PTEN has also been shown to contribute to AKT3 up-
regulation. siRNA knockdown of PTEN led to enhanced AKT3
phosphorylation in both melanocytes and humanmelanoma cells
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(Stahl et al., 2004). siRNA-mediated down-regulation of AKT3
conversely resulted in a decrease in cell survival and tumor growth
(Stahl et al., 2004; Tran et al., 2008). AKT3 has also been shown
to participate in resistance to BRAF inhibitors and suppression
of AKT3 may lead to increased clinical responses with BRAF
inhibitors (Shao and Aplin, 2010). AKT2 over-activation has also
been identiﬁed inmelanoma, breast, and ovarian cancer (Arboleda
et al., 2003; Yuan et al., 2003; Nogueira et al., 2010; Shin et al.,
2010). Expression of AKT2 in melanoma has been established
in several different models of melanoma; a mutant Ras back-
ground (Nogueira et al., 2010) and one with ectopic expression
of metabotropic glutamate receptor 1 (Grm1; Shin et al., 2010). In
the metabotropic glutamate receptor model (Pollock et al., 2003b;
Namkoong et al., 2007), examination of primary, nodal and in-
transit metastasis yieldedAKT2 and notAKT3 as the predominant
activated isoform. In subsequent studies, Akt was shown to be
a downstream target of Grm1 (Shin et al., 2010). Modulation
of Akt2 expression levels in an inducible siRNA system lead to
growth suppression in vitro and in vivo (Shin et al., 2010). Fur-
thermore, siRNA knockdown of GRM1 in human melanoma cell
also resulted in a decrease in AKT2 phosphorylation corroborat-
ing that AKT2 is a downstream target of GRM1 (Wangari-Talbot
et al., 2012). Nogueira et al. (2010) have also shown that PTEN loss
in a mutant RAS background can result in the selective activation
of AKT2. This up-regulation of AKT2 was found to contribute
to the increase in cell transformation, invasiveness of melanoma
cells and a reduction in E-cadherin expression. In addition, using
a complementary genetic approach, a dominant negative mutant
of AKT2 led to a decrease in the invasiveness of the melanoma
cells (Nogueira et al., 2010). Regardless of which AKT isoform is
involved in melanoma, the PI3K/AKT pathway is an important
therapeutic target in melanoma.
Several studies have pointed to the potential use of PI3K/AKT
inhibitors in suppressing tumor growth in vitro, in vivo as well as
in chemo-sensitization (Brognard et al., 2001; Stassi et al., 2005;
Sinnberg et al., 2009; Hirai et al., 2010; Isosaki et al., 2011). PI3K
inhibition by the irreversible inhibitor wortmannin or LY294002,
can block AKT activation as well as compensatory mechanisms
and has been used widely in mechanistic studies to dissect the
mode of action of this pathway (Vlahos et al., 1994; Wymann
et al., 1996; Garcia-Echeverria and Sellers, 2008). These two
compounds however have pharmaceutical limitations such as
off-target activities that prevent them from transitioning from
the bench to the clinic (Bain et al., 2003; Knight and Shokat,
2007). Based on the wortmannin model, compounds with fewer
limitations such as PWT-458 and PX-866 have been developed
but neither of them have entered clinical trials yet (Garcia-
Echeverria and Sellers, 2008). ZSTK474 a novel potent PI3K
inhibitor with anti-tumor efﬁcacy is undergoing safety assess-
ment in solid malignancies (Yaguchi et al., 2006). Other AKT
inhibitors such as isoselenocyanates, API-2, SR13668, BI-69A11,
GSK690693, and MK-2206 have been shown to have anti-tumor
activity in suppressing tumor growth and are undergoing further
testing (Forino et al., 2005; Karst et al., 2006; Rhodes et al., 2008;
Sharma et al., 2009; Hirai et al., 2010). In a clinical trial how-
ever, treatment with the AKT inhibitor perifosine/keryx showed
no objective responses in patients with metastatic melanoma and
had signiﬁcant gastrointestinal side effects (Ernst et al., 2005). AKT
inhibitors however may be helpful in patients with BRAFV600E
melanomas as Akt activation has been shown to cooperate
with the mutant B-Raf to promote progression and chemoresis-
tance (Tran et al., 2008; Shao and Aplin, 2010). It is therefore
not surprising that combinatorial therapies utilizing an AKT
inhibitor such as MK-2206 and the MEK inhibitor, AZD-6244,
in patients with relapsed BRAFV600E positive melanomas (clinical
trial NCT01510444) are in clinical testing. Another possibility in
targeting the AKT pathway in melanoma is through inhibition of
mTOR signaling using rapamycin or rapamycin analogs. These
mTOR inhibitors show anti-tumor properties in vitro, in vivo
and the ability to improve sensitivity to chemotherapeutic agents
(Faivre et al., 2006; Sinnberg et al., 2009). Treatment of melanoma
patients with the mTOR inhibitor sirolimus in combination with
carboplatin and paclitaxel displayed signiﬁcant tumor regression
(Meier et al., 2009). Promising results have also been observedwith
another mTOR inhibitor, evolorimus (Hainsworth et al., 2010; Si
et al., 2012).
CDKN2A/P16INK4A/ARF
Familial melanomas account for 8–12% of diagnosed melanomas
(Greene and Fraumeni, 1979; Fountain et al., 1992). Genetic stud-
ies in large melanoma-prone families have demonstrated that loss
of heterozygosity or mutations at the p16 locus co-segregate with
melanoma susceptibility in familial melanoma kindred (Hussus-
sian et al., 1994; Kamb et al., 1994; Berwick et al., 2006). The
9p21 locus encodes two distinct proteins; p16INK4A and p19Arf
in mouse/p14ARF in humans) and has been shown to undergo
frequent recombination and deletions in both spontaneous and
familialmelanoma (Kamb et al., 1994; Quelle et al., 1995). Exon 1α
and 1β of theCDKN2A gene are driven by two different promoters
which results in two alternate transcripts that share exons 2 and
3. The 1α transcript encodes the p16INK4A protein while the 1β
transcript encodes the p19Arf protein (Serrano et al., 1993; Quelle
et al., 1995). p16INK4A is involved in the regulationof the cell cycle
through its control of the RB-regulated G1–S transition (Serrano
et al., 1993; DePinho,1998; Sherr andRoberts, 1999),while p19Arf
acts as a tumor suppressor by stabilizing and enhancing p53 lev-
els through the blockade of MDM2-mediated p53 ubiquitination
and degradation (Chen et al., 1998; Kamijo et al., 1998; Pomerantz
et al., 1998; Zhang et al., 1998). Population-based studies have been
performed in an attempt to elucidate the lifetime risk of develop-
ingmelanoma in familieswith thesemutations (Bishop et al., 2002;
Berwick et al., 2006; Goldstein et al., 2007; Harland et al., 2008;
Cust et al., 2011). A study based on 80 melanoma-prone families
consisting of 402 melanoma patients and 713 non-affected family
members from North America, Europe, and Australia was used by
the Melanoma Genetics Consortium to calculate the lifetime pro-
jected risk of developing the disease in CDKN2A carriers (Bishop
et al., 2002). By age 80, the projected risk of developing melanoma
in North America was 76%, 91% in Australia, and 58% in Europe.
Analysis of the same sample for comparative risks conferred by
p16INK4A or p14ARF did not yield statistical signiﬁcant differ-
ences in the melanoma risk between the two mutations (Bishop
et al., 2002). Germ line INK4A mutations (Hussussian et al., 1994;
Kamb et al., 1994), polymorphisms in the 5′ and 3′ untranslated
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regions (UTRs) that alter translation or regulatemRNA stability of
p16INK4A and promoter mutations of p16INK4A are all genomic
alterations that have also been identiﬁed in association with 9p21-
linked familial melanoma (Liu et al., 1999; Kumar et al., 2001).
Studies have shown that inactivationof p16Ink4a increased suscep-
tibility to both spontaneous and carcinogen-induced melanoma
(Krimpenfort et al., 2001; Sharpless et al., 2001). p16INK4A has
also been reported to cooperate with other oncogenes to promote
melanomagenesis (Serrano et al., 1993; Chin et al., 1997; Ack-
ermann et al., 2005). The combination of p16INK4a deﬁciency
with activated H-Ras (Serrano et al., 1993; Chin et al., 1997), N-
Ras (Ackermann et al., 2005), and K-Ras (Monahan et al., 2010)
in mouse models have been shown to promote highly pene-
trant melanomas with short latency. Recently, p16INK4A has
also been shown to have a role in regulating cellular oxidative
stress. In response to potential DNA oncogenic stress such as
UV exposure, melanocytes were found to upregulate the expres-
sion of p16INK4A mediated by the p38 stress-activated protein
kinase (SAPK) pathway (Naidu et al., 2009; Jenkins et al., 2011).
In p16INK4A-deﬁcient cells, an increase in intracellular reactive
oxygen species (ROS), was noted even in the absence of exogenous
oxidative stress with restoration of p16INK4A found to restore
ROS levels to normal levels (Jenkins et al., 2011). Interestingly,
regulation of ROS by p16INK4A was found to be independent of
both its functions in cell cycle control as well as the retinoblas-
toma protein. Other studies have reported on possible roles of
p16INK4A outside of its cell cycle control functions. For example,
Becker et al. (2001) have shown that some p16INK4Amutants still
retain their ability to bind CDK4. The precise mechanism through
which p16INK4 regulates ROS remains elusive.
p19Arf controls the stability of the p53 tumor suppressor whose
activity is abrogated by point mutations in many tumors during
carcinogenesis (Greenblatt et al., 1994; Hollstein et al., 1994). In
melanoma, the pathological role of p53 is highly controversial as
primary and metastatic melanomas have been found to have low
incidences of p53 allelic loss or point mutations (Yang et al., 2001).
However, cases of highly penetrant and aggressive melanomas
involving p53 inactivation in mouse models have been reported
(Bradl et al., 1991). Bardeesy et al. (2001) have shown that a trans-
genic mouse model, Tyr-RAS/Trp53+/−, characterized by the loss
of a p53 allele but with retention of p19Arf develops melanoma.
Interestingly, a p19Arf deﬁciency in the Tyr-RAS;Ink4a/Arf−/−
mouse model with functional p53 was also found to develop
melanoma (Chin et al., 1997). This illustrates a reciprocal role of
p53 inactivation and loss of Arf suggesting that they have related
functions and that Arf may serve as a regulator of p53 (Sharp-
less and Chin, 2003). Various therapeutic strategies for restoring
wild-type p53 activity are under investigation. Small molecules
that stabilize p53 in its active biological conformation and anti-
bodies that bind the p53 carboxyl-terminus and restore its DNA
binding function have been shown to have apoptotic and chemo-
sensitization activity (Hupp et al., 1992, 1995). Additional strate-
gies involve the reactivation of p53 through inhibition of MDM2
using small molecules such as nutlin (Vassilev, 2004; Vassilev et al.,
2004). These strategies have had mixed results as CP-31398, a
compound found to stabilizewild-type p53 and rescuemutant p53
was found not to increase chemosensitivity in human melanoma
cells (Luu and Li, 2003). Recent studies have shown that p53 dys-
regulation in melanoma can also occur due to the up-regulation
of a negative regulator of p53, MDM4 in a signiﬁcant proportion
of stage I–IV melanomas (65%; Marine and Jochemsen, 2005).
Targeting the MDM4–p53 pathway using the small peptide SAH-
p53-8 that bindsMDM4 and disrupts MDM4–p53 complexes was
shown to result in tumor growth inhibition and sensitization
to chemotherapeutics including BRAF inhibitors (Gembarska
et al., 2012).
Although the insight obtained from studies on these pathways
inmelanoma has led to signiﬁcant improvements in drug develop-
ment, treatment, and patient survival, complete cure still remains
elusive. This is driving cutting edge research into discovering novel
drug targets that may lead to greater improvements in design of
therapies. Genomic sequencing of tumor genomes and exomes
has led to the identiﬁcation of genes with unexpected roles in
melanoma formation, progression, and resistance to therapy. In
the next section, we will discuss some of the novel targets iden-
tiﬁed from next generation sequencing high throughput screens
that allow the sequencing of random DNA fragments with large
coverage of the cancer genomes. Various changes such as rear-
rangements, copy number variations, base substitutions, and small
indels have been identiﬁedwith sufﬁcient coverage to identifymost
somatic mutations in an individual cancer genome (Pleasance
et al., 2010).
GENOMIC SEQUENCING OF MELANOMA
Whole genome sequencing has allowed the identiﬁcation of muta-
tional signatures in multiple tumor types including melanoma
(Ley et al., 2008; Pleasance et al., 2010; Link et al., 2011; Puente
et al., 2011; Welch et al., 2011). Pleasance et al. (2010) reported on
the ﬁrst comprehensive somatic mutation screen of melanoma
performed in the COLO-829 melanoma cell line. A total of
33,345 somatic base substitutions, 292 of them in protein cod-
ing sequences were recognized. Two of these somatic substitutions
were identiﬁed in SPDEF, an ETS transcription factor family,
which has been associated with progression of breast and prostate
cancer (Sood et al., 2007). Further sequencing of 48 additional
melanoma biopsy samples conﬁrmed the presence of these base
pair substitutions as well as a third somatic mutation in SPDEF.
A missense mutation was also identiﬁed in UVRAG, a putative
tumor suppressor that complements the ultraviolet sensitivity of
xeroderma pigmentosum group C cells and also has a role in
autophagy (Kim et al., 2008). In addition, an 8- to 12-fold increase
in copy number on chromosome 3p which contains four com-
plete genes: RARB, TOP2B, NGLY1, and KS (OXSM) and a four-
to sixfold increase on chromosome 15 containing MKRN3 and
NDN genes were noted. It is important to point out that this was
the ﬁrst instance that these ampliﬁed candidate genes were impli-
cated in cancer development. This study also identiﬁed a high
rate of C to T transitions in the tumor samples that have been
reported to be signatures associated with UV exposure (Daya-
Grosjean and Sarasin, 2005; Pfeifer et al., 2005), suggesting that
UV-induced DNA damage could have resulted in the pathogenesis
of COLO-829 melanoma cells (Pleasance et al., 2010).
Turajlic et al. (2012) also performed whole genome sequenc-
ing on primary acral melanoma and matched lymph node
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metastasis from the same patient. A total of 12,661 base sub-
stitutions were identiﬁed in the primary acral melanoma while
11,711 base substitutions were identiﬁed in the metastatic spec-
imen. Several single nucleotide polymorphisms were identiﬁed
in IFNA16, which is within the melanoma susceptibility locus
on 9p21, MSH2, APC, and MEN1 and novel variants of BRCA1
and ERCC2 with the later two genes involved in DNA repair.
Genomic ampliﬁcation of several chromosomal regions; 4q12,
11q13, 11q14, 17p11, and 20q11 as well as of the receptor
tyrosine kinase gene, KIT, were detected in both primary and
metastatic samples. Other additional ﬁndings were the common
C to T transitions at the 3′ base of pyrimidine di-nucleotides
(TpC or CpC) associated with UV exposure (Daya-Grosjean and
Sarasin, 2005; Pfeifer et al., 2005) indicating that similar to cuta-
neous melanomas, acral melanomas are just as susceptible to
UV-induced DNA damage that contributes to melanoma devel-
opment (Turajlic et al., 2012). Another genomic screen of acral
melanomas likewise showed a high prevalence of UV associated
C to T transitions in tumor samples consistent with melanomas
arising from chronic sun exposure (Berger et al., 2012). A sig-
niﬁcant chromosomal rearrangement was found in the PREX2
locus, which encodes a PtdIns(3,4,5)P3 RAC exchange factor
recently shown to interact with and modulate the function of
PTEN (Fine et al., 2009). In addition to the nine somatic rear-
rangements detected near the PREX2 locus, ampliﬁcation of
PREX2 was also identiﬁed in the tumor samples. Sequencing
of another tumor cohort in the evaluation of PREX2 muta-
tions found a 14% frequency in non-synonymous mutations.
Functional signiﬁcance was assessed using truncation mutants
and non-synonymous point mutations of PREX2. In compar-
ison to wild-type PREX2, the over-expressed mutants showed
accelerated tumorigenicity suggesting that some melanoma
cells may gain oncogenic activity through PREX2 mutations
(Berger et al., 2012).
Exome screenings are another mechanism being used to exam-
ine melanoma tumor mutations. Wei et al. (2011) performed
exome sequencing on 14 matched pairs of normal and metastatic
tumor DNAs from untreated individuals with melanoma and
focused on genes altered in more than two tumor samples. The
common BRAFV600E mutation was detected in 7 out of the 14
samples, while 9 other genes harboring recurrent mutations were
also identiﬁed. One of these genes, TRRAP encodes a transfor-
mation/transcription domain-associated protein and functions as
a component of a multi-protein co-activator complex possessing
histone acetyltransferase activity that is central to the transcrip-
tional activity of p53, c-MYC, and E2F1. TRRAP had a recurring
serine tophenylalaninemutation at amino acid residue 722 in 6out
of the 14 samples suggesting that this might bemutational hotspot
inmelanoma. The clustering of thismutation is similar to the clus-
tering of activation mutations found in BRAF, NRAS, or PIK3CA
in melanoma suggesting it might be an oncogene. To assess the
consequences of these substitutions on melanoma cells, knock-
down of mutated TRRAP in melanoma cells resulted in increased
apoptosis suggesting that theseTRRAP mutations might be essen-
tial in the survival of melanoma cells. This screen also uncovered
mutations in GRIN2A, an ionotropic (N-methyl-D-aspartic acid,
NMDA) glutamate receptor subunit ε-1 in 6 out of the initial 14
samples as well as in 25.2% of additional melanoma biopsies and
cell lines analyzed. The number of C to T transitions observed in
GRIN2Awas also signiﬁcantly higher than the number of the other
nucleotide substitutions. Twomutational clusters, and three recur-
rent mutations were found in evolutionarily conserved domains
which by SIFT analysis are predicted to have protein function
(Wei et al., 2011). The identiﬁcation of this glutamate receptor
supports the data by Chen and colleagues who have shown that an
aberrantly expressedmetabotropic glutamate receptor (Grm1) can
result inmelanocytic transformation in vitro and tumorigenesis in
vivo (Zhu et al., 1998; Pollock et al., 2003b). In addition, signiﬁcant
subsets of human melanoma tumors express the human form of
the receptor, GRM1 (Namkoong et al., 2007; Lee et al., 2011). In
two completed clinical trials, targeting the glutamatergic signal-
ing mediated by GRM1 expression led to mixed clinical responses,
pointing to the need of a better understanding of glutamatergic
signaling and melanoma (Yip et al., 2009; Mehnert et al., 2011,
2012). Activating mutations in another metabotropic glutamate
receptor GRM3, was also identiﬁed in an exon capture screen of
G protein-coupled receptors in melanoma (Prickett et al., 2011).
The initial screen showed that GRM3 had a 16.3% mutation rate
with 18 non-synonymous mutations in 13 of 80 tumors while
a screen of an additional tumor cohort of 57 samples detected
a 15.7% mutation rate. Among the mutations detected in GRM3,
theGlu870Lysmutationwas identiﬁed in 4 samples suggesting that
this is likely a mutational hotspot in this gene. Functional screens
performed with cells transformed with mutated GRM3 showed
enhanced activation of MEK1/2, increased migration in vitro and
pulmonary metastasis in xenograft models. Interestingly, it was
also shown that cells with GRM3 activation mutations are more
responsive to treatment with the MEK inhibitor AZD-6244 than
GRM3wild-type cells (Prickett et al., 2011). GRM3might turn out
to be an important player in melanoma as an independent exome
screen from the Halaban group also identiﬁed it as one of the
genes with a high mutation burden in sun-exposed melanomas
(Krauthammer et al., 2012). Furthermore, given the low success
rates observed with MEK inhibitors, GRM3 activating mutations
could be a predictor of MEK inhibitor responsive tumors (Prickett
et al., 2011).
Krauthammer et al. (2012) performed an exome sequencing
of 147 primary and metastatic tumors which was a signiﬁcantly
bigger sample size than analyzed previously by other groups. Com-
parison of the 147 melanomas with matched samples revealed
23,888 missense mutations, 1,596 non-sense mutations, 399
splice-site variants, and 282 insertions/deletions. Comparative
analysis of sun-exposed versus sun-shielded melanomas showed
that sun-exposed melanomas found on the trunks, arms, legs,
and head had a higher prevalence of somatic mutations com-
pared to the sun-shielded acral, mucosal, and uveal melanomas.
In addition, tumors from older patients were found to contain
more mutations than those in younger people with the primary
lesions of the older patients found in the head and neck, which
is indicative of melanomas arising due as a result of chronic
sun damage. Based on sun exposure and mutation burden, the
investigators were able to classify the tumors into three distinct
groups corresponding to the number of mutations present namely,
high, medium, and low mutation count. These mutations likely
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originated in lesions from chronically exposed, intermittently sun-
exposed and sun-shielded skin regions, respectively. Similar to
other exome sequencing studies, a signiﬁcant proportion of the
single base pair mutations included C > T transversions associ-
ated with UV-inducedDNA damage. Furthermore, they identiﬁed
amotif, TTTCGT, enriched in sites where three ormoremutations
were found on sun-exposed skin suggesting a potential hotspot
for the formation of cyclobutane pyrimidine dimers which are
associated with lesions arising after UV exposure. Of the genes
found to be frequently mutated,BRAF andNRAS featured promi-
nently in lesions found on sun-exposed areas. Most interesting, a
novel recurrent mutation was also identiﬁed in these sun-exposed
melanomas. The recurrent mutation identiﬁed in seven of the
tumor samples was a substitution of a proline for a serine at
amino acid 29 in RAC1 (Ras-related C3 botulinum toxin substrate
1; RAC1P29S), a small Rho GTPase family protein with roles in
proliferation, migration, and cytoskeletal rearrangements. Anal-
ysis of an additional set of 364 tumors detected the RAC1P29S
mutation in 20 of the samples (9.2%) and also in 4 out of 76
cell lines (5.3%) derived from sun-exposed tumors. There was
no difference in the frequency of the mutation in primary versus
metastatic tumors. Of note however, is the higher frequency in
men (12.8%) versus women (2.4%) attributed to higher rates of
UV exposure in men than women. In in vitro assays, RAC1P29S
was shown to be a gain of function mutation, 4.5-fold more
active in its GTP-bound state compared to the wild-type protein.
In transiently transfected cells, RAC1P29S was shown to exhibit
increased binding to the downstream effectors PAK1 and MLK3,
enhance ERK phosphorylation, cell proliferation, and migration
in comparison to thewild-type protein. In addition, it appears that
RAC1P29S frequently associates with the netrin 1 receptor, DCC, a
tumor suppressor which can mediate signals that promote prolif-
eration and migration. It is possible that RAC1P29S and DCC loss
cooperate in a manner similar to that of PTEN loss and muta-
tions in BRAF or RAS in promoting melanoma tumor growth. In
addition, they also found several mutated genes in sun-shielded
melanomas. Mutations in DYNC1I1 dynein, cytoplasmic 1, inter-
mediate chain 1,which encodes a proteinwith roles inmicrotubule
motor activity, progression through the spindle assembly check-
point, and normal chromosome segregation were found in 3 of
17 acral melanomas. A second RAC1 mutation, due to a substitu-
tion in amino acid 65, Asp65Asn, was found also found in acral
melanomas. In six uveal melanomas, mutations in BAP1 were
also identiﬁed. Thus it appears that distinct mutational signatures
exist in lesions depending on the amount of sun exposure and the
resulting UV-induced DNA damage. Further, the newly identiﬁed
RAC1P29S may have therapeutic potential given its cancer-related
signaling.
Chin and colleagues similarly reported on a whole exome
sequencing study in which they examined paired tumor and
normal DNA from 135 melanoma patients in a challenge to
differentiate passenger mutations from driver mutations (Hodis
et al., 2012). Over 83,000 mutations were identiﬁed, with most
of them non-synonymous which may suggest that they are pas-
senger mutations and not drivers. In this study, and similar to
the previously discussed reports mutation signatures associated
with UV exposure were highly predominant. Permutation based
framework was used to identify non-silent mutations with pre-
dicted functional signiﬁcance which identiﬁed eleven genes with
high signiﬁcant mutation burdens that included BRAF, NRAS,
TP53, PTEN, P16INK4A, and MAP2K, as well as new candi-
dates that included RAC1, PPP6C, SNX31, TACC1, and STK19.
It is important to note that RAC1 and PPP6C were also identi-
ﬁed in the screen by Krauthammer et al. (2012). In this study,
RAC1P29S was also shown to have increased effector binding as
well as increased association with GTP compared to the wild-type
protein. In addition, they also identiﬁed MAP2K1 as a mutated
gene in melanoma, with a recurrently mutated hotspot which
conﬁrmed a prior report (Nikolaev et al., 2012). It is important
to note that despite converging on some of the same genes using
different analysis methodology, there are disparities with genes
identiﬁed in one screen and not identiﬁed in another which may
be due to the ﬁlters applied for each analysis. Regardless, the
permutation framework applied by Chin and colleagues for this
analysis may be especially useful for screening bigger sample sizes
(Hodis et al., 2012).
Whole exome sequencing is also been used to investigate
acquired resistance resulting in drug relapse in patients treated
with BRAF inhibitors such as vemurafenib (Shi et al., 2012). In
a study by Shi et al. (2012), 20 sets of matched pre- and post-
vemurafenib treatment biopsy samples were subjected to whole
exome sequencing. An increase in BRAFV600E copy number (2-
to 14-fold) was noted in patients who initially responded then
relapsed with disease progression. In addition, an increase in
mutant BRAF to wild-type BRAF ratio was also noted in the
patient samples that showed increased BRAFV600E copy num-
ber suggesting the possible selection for the mutant genotype
during the resistance acquisition process. This selection was
conﬁrmed in experiments performed in vemurafenib resistant
humanmelanoma cell lines derived fromBRAFV600E-vemurafenib
responsive cells lines under continuous drug exposure. Further-
more, they showed that drug saturation of the mutant BRAFV600E
protein could be achieved by increasing the dose as copy num-
ber gain conferred resistance to a lower concentration (1 μM) but
not a higher concentration (10 μM) implying that dose escala-
tion of vemurafenib or other BRAF inhibitors might overcome
the acquired resistance (Shi et al., 2012).
Genomic studies have played signiﬁcant roles in improv-
ing treatment protocols for melanoma by expanding our ability
to design targeted therapies. In addition, we have also gained
insight on how to modify these therapies to achieve maximal
results through different combination therapies. Monotherapies
for melanoma have been shown to slow disease progression and
also increase survival with varying success. Combination therapies
have emerged as means to increase survival and long-term remis-
sions. Importantly, it is now easier to predict whether a patient is
likely to respond to a particular form of therapy due to the muta-
tional signatures of their tumors. Next generation sequencing and
other high throughput screens also continue to uncover genes with
novel oncogenic properties in melanoma which open opportuni-
ties for drug design. Furthermore, algorithms and permutations
maymake the process of analyzing large samples and sortingmuta-
tions based on signiﬁcance and potential functions a less complex.
The clinical potential of some of these novel melanoma candidate
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genes, such asGRM3 are already clear and given the speed at which
modern science is advancing, we can speculate that the informa-
tion gained from these sequencing studies will in the future be
applied toward clinical medicine. Moreover, it is important to also
take note of the not so surprising revelations of these sequencing
projects especially as they relate to UV exposure and its role in
DNA damage and melanoma formation. With an increase in sun
seeking behavior and tanning, it is critical that this information is
shared with the general public population in the hope that behav-
ior modiﬁcation will occur in order to reverse the rising incidence
of melanoma.
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